摘要
目的探讨雾化吸入大剂量布地奈德、博利康尼治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法将44例慢性阻塞性肺疾病急性加重期患者随机分为两组,在常规综合治疗的基础上,治疗组给予大剂量布地奈德混悬液4 mg、博利康尼5 mg雾化液以氧气驱动为动力雾化吸入;对照组给予甲强龙40 mg静滴,博利康尼5 mg以氧气驱动为动力雾化吸入。观察治疗一周后二组患者症状和体征的改善情况。结果治疗组总有效率为90.9%,优于对照组的77.2%有统计学意义(P<0.05)。结论雾化吸入大剂量布地奈德、博利康尼治疗慢性阻塞性肺疾病急性加重期有明显疗效。
Objective To explore the clinical efficacy of aerosol inhalation large dose of budesonide and bricanyl on AECOPD.Methods 44 cases of chronic obstructive pulmonary disease in patients with acute aggravating period were randomly divided into two groups. In treatment group, 4mg budesonide suspension liquid and 5mg bricanylatomized liquidinhaled by oxygen drive aerosol inhalation; In matched groupmethylprednisolone 40 mg were given intravenous drip, accompanying 5mg bricanylatomized liquidinhaled by oxygen drive aerosol inhalation. After a week, physical symptoms and sign were observed in two groups. ResultsIn treatment group, total effective rate was 90.9%,however, the effective rate was only 77.2% in control group. The result was statisticaly significant .ConlusionAerosol inhalation large dose of budesonide and bricanyl has obvious curative effect on AECOPD patients.
出处
《中国卫生标准管理》
2015年第2期76-77,共2页
China Health Standard Management
